ask why
Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

The papers that matter: 15 July to 21 July 2024

The 1 most important of the 1 papers published that week and summarised on Y, ranked by what verified readers said would change practice, then by strength of design and size. Secondary analyses come last.
Oncology · Cancer Commun (Lond) · 2024-07-17

Secondary analysis of the phase III AENEAS trial: in 106 patients with untreated EGFR-mutated advanced NSCLC and baseline CNS metastases, aumolertinib prolonged median CNS PFS vs gefitinib (29.0 vs 8.3 months; HR 0.31). No new safety findings.

Secondary analysisn = 106
Lu et al. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)

Previous weekNext weekAll weeks

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.